S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility

Biochemical and Biophysical Research Communications

Volumn 447, Issue 3, 2014, Pages 459-464

  Chen, Na ^a   Sato, Daisuke ^a   Saiki, Yuriko ^a   Sunamura, Makoto ^a   Fukushige, Shinichi ^a   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell proliferation; Lung cancer; Migration; PRDM2; S100A4

Indexed keywords

CALVASCULIN;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; METASTASIS; MICROARRAY ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL PROLIFERATION; LUNG CANCER; MIGRATION; PRDM2; S100A4;

CARCINOGENESIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; S100 PROTEINS; TRANSCRIPTION FACTORS;

EID: 84900342109     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.025     Document Type: Article

References (29)

1. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005, 23:2513-2520.
2. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355:479-485.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63:11-30.
4. Schneider M., Hansen J.L., Sheikh S.P. S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in disease?. J. Mol. Med. 2008, 86:507-522.
5. HUGO Gene Nomenclature Committee. http://www.genenames.org/.
6. Matsumoto K., Irie A., Satoh T., Ishii J., Iwabuchi K., Iwamura M., Egawa S., Baba S. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 2007, 70:602-607.
7. Rudland P.S., Platt-Higgins A., Renshaw C., West C.R., Winstanley J.H.R., Robertson L., Barraclough R. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res. 2000, 60:1595-1603.
8. Hemandas A.K., Salto-Tellez M., Maricar S.H., Leong A.F.P.K., Leow C.K. Metastasis-associated protein S100A4 - a potential prognostic marker for colorectal cancer. J. Surg. Oncol. 2006, 93:498-503.
9. Cho Y.G., Nam S.W., Kim T.Y., Kim Y.S., Kim C.J., Park J.Y., Lee J.H., Kim H.S., Lee J.W., Park C.H., Song Y.H., Lee S.H., Yoo N.J., Lee J.Y., Park W.S. Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. APMIS 2003, 111:539-545.
10. Rosty C., Ueki T., Argani P., Jansen M., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 2002, 160:45-50.
11. Gupta S., Hussain T., MacLennan G.T., Fu P., Patel J., Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J. Clin. Oncol. 2003, 21:106-112.
12. Tabata T., Tsukamoto N., Abbas A., Fooladi I., Yamanaka S., Furukawa T., Ishida M., Sato D., Gu Z., Nagase H., Egawa S., Sunamura M., Horii A. RNA interference targeting against S100A4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2009, 390:475-480.
13. Sekine H., Chen N., Sato K., Saiki Y., Yoshino Y., Umetsu Y., Jin G., Nagase H., Gu Z., Fukushige S., Sunamura M., Horii A. S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2012, 429:214-219.
14. Tsukamoto N., Egawa S., Akada M., Abe K., Saiki Y., Kaneko N., Yokoyama S., Shima K., Yamamura A., Motoi F., Abe H., Hayashi H., Ishida K., Moriya T., Tabata T., Kondo E., Kanai N., Gu Z., Sunamura M., Unno M., Horii A. The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas 2013, 42:1027-1033.
15. Kimura K., Endo Y., Yonemura Y., Heizman C.W., Schafer B.W., Watanabe Y., Sasaki T. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int. J. Oncol. 2000, 16:1125-1131.
16. Zhang H., Liu J., Yue D., Gao L., Wang D., Zhang H., Wang C. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J. Clin. Pathol. 2013, 66:937-945.
17. Matsubara D., Niki T., Niki T., Ishikawa S., Goto A., Ohara E., Yokomizo T., Heizmann C.W., Aburatani H., Moriyama S., Moriyama H., Nishimura Y., Funata N., Fukayama M. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci. 2005, 96:844-857.
18. Takeshita H., Sato M., Shiwaku H.O., Semba S., Sakurada A., Hoshi M., Hayashi Y., Tagawa Y., Ayabe H., Horii A. Expression of the DMBT1 gene is frequently suppressed in human lung cancer. Jpn. J. Cancer Res. 1999, 90:903-908.
19. Yamanaka S., Gu Z., Sato M., Fujisaki R., Inomata K., Sakurada A., Inoue A., Nukiwa T., Kondo T., Horii A. SiRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 2008, 75:2-8.
20. Yamanaka S., Sunamura M., Furukawa T., Sun L., Lefter L.P., Abe T., Yatsuoka T., Fujimura H., Shibuya E., Kotobuki N., Oshimura M., Sakurada A., Sato M., Kondo T., Matsuno S., Horii A. Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor suppressor gene that suppresses angiogenesis. Lab. Invest. 2004, 84:1339-1351.
21. Xu S., Furukawa T., Kanai N., Sunamura M., Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 2005, 50:159-167.
22. Kato C., Kojima T., Komaki M., Mimori K., Duarte W.R., Takenaga K., Ishikawa I. S100A4 inhibition by RNAi up-regulates osteoblast related genes in periodontal ligament cells. Biochem. Biophys. Res. Commun. 2005, 326:147-153.
23. Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., Hatakeyama K., Saya H. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
24. Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem. Biophys. Res. Commun. 2012, 421:98-104.
25. Kondo E., Horii A., Fukushige S. The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J. Biochem. 1999, 125:818-825.
26. Buyse I.M., Shao G., Huang S. The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:4467-4471.
27. Chadwick R.B., Jiang G.-L., Bennington G.A., Yuan B., Johnson C.K., Stevens W.M., Nieman T.H., Peltomäki P., Huang S., de la Chapelle A. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2662-2667.
28. Sakurada K., Furukawa T., Kato Y., Kayama T., Huang S., Horii A. RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and colorectum. Genes Chromosome Cancer 2001, 30:207-211.
29. He L., Yu J.-X., Liu L., Buys I.M., Wang M.-S., Yang Q.-C., Nakagawara A., Brodeur G.M., Shi Y.E., Huang S. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 1998, 58:4238-4244.